ProKidney FY2023 net loss $135.4M; cash $363M; positive Phase 2 data; mfg pause

PROKIDNEY CORP.

Net loss before noncontrolling interest $135.4M vs $148.1M in 2022; cash $363.0M, funding into Q4 2025.
R&D expenses $106.7M, up $24.6M on Phase 3 costs; G&A $44.8M, down $26.1M on lower equity comp.
Appointed Dr. Bruce Culleton as CEO and Nikhil Pereira-Kamath as Chief Business Officer.
Positive interim Phase 2 RMCL-002 data showed kidney function preservation; PROACT 1 enrollment modified to eGFR 20-35.
Manufacturing paused for protocol amendment and QP audit; expects PROACT 1 and PROACT 2 enrollment to resume mid-2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PROKIDNEY CORP. reported financial results for the year ended December 31, 2023.

Period: the year ended December 31, 2023
Result: reported results

Exact text from the filing

ProKidney Corp. issued a press release to announce its financial results for the year ended December 31, 2023.

View on SEC.gov

1050 earnings releases filed in the last 30 days. Browse all earnings releases →

PROKIDNEY CORP. filing history →

Source: SEC EDGAR

accession 0000950170-24-034961

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.